Attendance at the conference is by invitation only. A live audio-only webcast of the presentation will be broadcast via the Internet. Those interested in listening to the webcast may access it at http://www.wsw.com/webcast/mdb/upi/, or through Uroplastys website at www.uroplasty.com. A link to the archived presentation will be available on the Uroplasty website.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the continued commercialization of our Urgent® PC system, which we believe is the only FDA-approved minimally invasive neuromodulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence - symptoms often associated with overactive bladder. We also offer Macroplastique®, an injectable bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Please visit Uroplasty, Inc. at http://uroplasty.com.
For Further Information: Uroplasty, Inc. David Kaysen, President and CEO, or Medi Jiwani, Vice President, CFO, Treasurer 952.426.6140 | EVC Group Doug Sherk (Investors), 415.896.6820 Chris Gale (Media), 646.201.5431 | |
SOURCE Uroplasty, Inc.